Betta Pharmaceuticals Co Ltd (300558) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Betta Pharmaceuticals Co Ltd (300558) has a cash flow conversion efficiency ratio of 0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥224.45 Million ≈ $32.84 Million USD) by net assets (CN¥5.92 Billion ≈ $866.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Betta Pharmaceuticals Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Betta Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Betta Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See what is Betta Pharmaceuticals Co Ltd's book value for net asset value and shareholders' equity analysis.
Betta Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Betta Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EQB Inc.
TO:EQB
|
0.073x |
|
Medical Properties Trust, Inc.
NYSE:MPT
|
-0.003x |
|
COSCO SHIPPING Specialized Carriers Co Ltd
SHG:600428
|
0.109x |
|
Sigma Advanced Systems Limited
NSE:MEGASOFT
|
-0.777x |
|
Chemours Co
NYSE:CC
|
0.487x |
|
Shanghai Bright Power Semiconductor
SHG:688368
|
0.045x |
|
Jiangsu Leili Motor Corp Ltd
SHE:300660
|
0.022x |
|
Hayward Holdings Inc
NYSE:HAYW
|
-0.093x |
Annual Cash Flow Conversion Efficiency for Betta Pharmaceuticals Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Betta Pharmaceuticals Co Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see 300558 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥6.67 Billion ≈ $975.69 Million |
CN¥911.26 Million ≈ $133.35 Million |
0.137x | -15.01% |
| 2024-12-31 | CN¥5.67 Billion ≈ $829.13 Million |
CN¥911.17 Million ≈ $133.33 Million |
0.161x | -5.87% |
| 2023-12-31 | CN¥5.35 Billion ≈ $783.09 Million |
CN¥914.23 Million ≈ $133.78 Million |
0.171x | +176.12% |
| 2022-12-31 | CN¥4.96 Billion ≈ $725.47 Million |
CN¥306.74 Million ≈ $44.89 Million |
0.062x | -44.95% |
| 2021-12-31 | CN¥4.69 Billion ≈ $685.68 Million |
CN¥526.63 Million ≈ $77.06 Million |
0.112x | -27.90% |
| 2020-12-31 | CN¥4.14 Billion ≈ $606.47 Million |
CN¥646.02 Million ≈ $94.53 Million |
0.156x | -30.66% |
| 2019-12-31 | CN¥2.47 Billion ≈ $361.32 Million |
CN¥555.07 Million ≈ $81.22 Million |
0.225x | +76.15% |
| 2018-12-31 | CN¥2.24 Billion ≈ $328.39 Million |
CN¥286.40 Million ≈ $41.91 Million |
0.128x | -5.22% |
| 2017-12-31 | CN¥2.07 Billion ≈ $302.40 Million |
CN¥278.26 Million ≈ $40.72 Million |
0.135x | -36.19% |
| 2016-12-31 | CN¥1.93 Billion ≈ $282.28 Million |
CN¥407.05 Million ≈ $59.56 Million |
0.211x | -51.08% |
| 2015-12-31 | CN¥893.95 Million ≈ $130.81 Million |
CN¥385.56 Million ≈ $56.42 Million |
0.431x | -15.62% |
| 2014-12-31 | CN¥543.03 Million ≈ $79.46 Million |
CN¥277.55 Million ≈ $40.61 Million |
0.511x | -14.31% |
| 2013-12-31 | CN¥319.10 Million ≈ $46.69 Million |
CN¥190.34 Million ≈ $27.85 Million |
0.596x | -31.05% |
| 2012-12-31 | CN¥172.56 Million ≈ $25.25 Million |
CN¥149.29 Million ≈ $21.85 Million |
0.865x | +29.97% |
| 2011-12-31 | CN¥52.28 Million ≈ $7.65 Million |
CN¥34.80 Million ≈ $5.09 Million |
0.666x | -- |
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma… Read more